Global Biopharmaceutical Company - Bristol Myers Squibb

2022 Fourth Quarter and Full-Year Results

Bristol Myers Squibb reports fourth quarter revenues of $11.4 billion; GAAP EPS of $0.95 and non-GAAP EPS of $1.82 which includes a net impact of ($0.01) per share due to Acquired IPRD charges and licensing income.

Bristol Myers Squibb posts full-year 2022 revenues of $46.2 billion; GAAP EPS of $2.95 and non-GAAP EPS of $7.70 which includes a net impact of ($0.24) per share due to Acquired IPRD charges and licensing income. 

Read more, including important cautionary statements about forward-looking information.

Our Stories


Cancer care milestone reached in Lesotho >


A cancer patient has received the first chemo infusion ever given within the country of Lesotho, in part, because of the work of the Bristol Myers Squibb Foundation. Read more about their global impact on access to cancer treatment.


Meet Tabitha >


After Tabitha and her mother both experienced a pulmonary embolism, their love and support for each other allow them to keep moving forward. Watch Tabitha’s inspiring story as she continues to lead a life filled with adventure.


Get to know Monique Phillips >


As global lead of the Black Organization for Leadership & Development (BOLD), Monique discusses how the group strives to engage and invest in Black talent and how her background in science has shaped her leadership.

Collaboration and dialogue drive success in multiple myeloma research

Bristol Myers Squibb is addressing patients' needs by exploring new approaches in multiple myeloma treatment and continuing research to further improve outcomes.


Bristol Myers Squibb continues to advance research to unlock the full potential of BCMA-targeted therapies across approaches in an effort to bring new options to patients living with multiple myeloma.

white blood cells 3D view

Bristol Myers Squibb is continuing to examine the immune system from multiple perspectives in order to find complementary combinations of therapies that have the potential to improve outcomes for patients.

Global Patient Week


Now in its eighth year, Global Patient Week is an essential part of our culture — it unifies us and reignites our passion to do more for our patients. As the first biopharma to set aside time solely focused on the individuals we are working for each and every day, Global Patient Week is a pinnacle of our year-round vision to transform patients’ lives through science.


Mary Jean, Pennsylvania, United States

Meet Mary Jean

Mary Jean lives with a type of hereditary heart condition known as hypertrophic cardiomyopathy (HCM), that often keeps her from doing the things she loves. Despite her condition, she is determined to live a normal life and take in all the richness life has to offer. Hear her inspirational story and learn what motivates her resilience.


Leading with our Value of Inclusion


Moving forward. Together.

Survivorship Today

Emmy award winner Sterling K. Brown explores what it means to live with cancer in a series of conversations with survivors from across the country.


We’re looking for people who want to change lives.  Join us as we transform patients’ lives through science. 


Learn more about how we strive to produce sustained strong performance and shareholder value.


Looking for answers?


Quick links to helpful resources.


Clinical Trial Information for researchers
Clinical trials and research are a critical part of bringing new medicines to patients.

Medical Information for healthcare providers
Information and resources to assist with caring for patients.

Help paying for your medicines
If you are a patient in the U.S. struggling to understand your coverage or pay for your medication, we may be able to help.
A heritage of improving lives through innovation >

Our company’s legacy of innovation began in the early 1800s, when our founders made it their mission to bring better health solutions to patients who needed them most. Today, we are continuing that tradition by using the latest science and technology to help improve lives through the research and development of new medicines for serious diseases.